Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Embelin is a naturally occurring benzoquinone compound primarily isolated from the dried berries of the Embelia ribes plant. It has a long history of use in traditional medicine systems, particularly in Ayurveda, for its antihelminthic and contraceptive properties[1][9]. Modern pharmacological research has identified embelin as a potent small-molecule inhibitor of X-linked inhibitor of apoptosis protein (XIAP), making it unique among non-peptide molecules targeting this anti-apoptotic protein[1][3]. Embelin exhibits multiple biological activities including antitumor (notably against prostate cancer), cytotoxic, antioxidant, anti-inflammatory (notably via NF-kappaB inhibition), and chemopreventive effects[1][3][4]. It also shows potential therapeutic benefits in autoimmune diseases such as multiple sclerosis by modulating immune cell differentiation and inflammatory pathways[2]. Additionally, preclinical studies suggest roles in diabetes management without promoting weight gain[5], myocardial protection through antioxidant/antiapoptotic mechanisms[3], and wound healing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on embelin.